For the treatment of tardive dyskinesia

Approved for the treatment of tardive dyskinesia (TD) in adults.

Trade name Austedo.

For the treatment of chorea associated with Huntington’s disease.

The approval as a TD treatment comes less than 5 months after valbenazine became the first drug approved as a treatment for the movement disorder.

It is a selective vesicular monoamine transporter 2 (VMAT2) inhibito.

Adverse effects of deutetrabenazine include akathisia, agitation, restlessness, sedation, nasopharyngitis, and insomnia.

Leave a Reply

Your email address will not be published. Required fields are marked *